Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | CID-5951923 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
mRNA | Mdivi-1 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.7 |
mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.017 | 0.7 |
mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.017 | 0.7 |
mRNA | N9-isopropylolomoucine | CTRPv2 | pan-cancer | AAC | 0.016 | 0.7 |
mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |
mRNA | BRD-K27986637 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.7 |
mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.015 | 0.7 |
mRNA | BRD-K49290616 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.7 |